Biosimilars: A Decade of Experience and Future Directions
Strategies for Improving Biosimilar Adoption and the Potential Role of Clinical Pharmacology
This public webinar was hosted by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) and the U.S. Food and Drug Administration (FDA).
Leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology shared their experience with biosimilars, their perspectives on how to improve the efficiency of biosimilar evaluations, and how to increase biosimilar adoption, including the role of clinical pharmacology.
April 13, 2022
1:00 p.m. – 3:30 p.m. ET
|
Welcome |
Maureen Kane, Ph.D. |
|
|
Opening Remarks |
Yow-Ming Wang, Ph.D. U.S. Food & Drug Administration |
Slides | |
|
Biosimilars in Oncology |
Gary Lyman, M.D., M.P.H., FACP, FRCP (Edin), FASCO |
|
|
Biosimilars in Rheumatology (and Immune Mediated Inflammatory Diseases) |
Allan Gibofsky, M.D., J.D., MACR, FACP, FCLM |
|
|
Biosimilars in IBD: Real World Evidence |
Gary Lichtenstein, M.D., FACP, FACG, AGAF |
|
|
Biosimilar Insulin Concepts |
Zachary Bloomgarden, M.D., MACE, FASPC Icahn School of Medicine at Mount Sinai |
|
|
Panel Discussion |
Yow-Ming Wang, Ph.D. U.S. Food and Drug Administration Sarah Yim, M.D. U.S. Food and Drug Administration Zachary Bloomgarden, M.D., MACE, FASPC Icahn School of Medicine at Mount Sinai Allan Gibofsky, M.D., J.D., MACR, FACP, FCLM Weill Cornell Medical College Gary Lichtenstein, M.D., FACP, FACG, AGAF University of Pennsylvania Gary Lyman, M.D., M.P.H., FACP, FRCP (Edin), FASCO University of Washington |
Top